The present proniosomal gel investigation was aimed to minimize the adverse effect associated with present topical proniosomal formulation and made to enhance its bioavailability and sustain release by noval pronisomal class of drug for treatment of rosacea. Oxymetazoline hydrochloride is a direct-acting alpha sympathomimetic and adrenergic agonist used to treat rosacea, a facial redness or ocular inflammation involving both the vesicular and tissue stroma. The pathology of rosacea was unknown, and was expected to hot beverages, alcohol consumption, high environmental temperature, sun exposures, menopause exacerbate the rosacea symptoms such as eythema, rash, and telangiectasia. Direct vasoconstriction of both the small arteries and veins has been established. Proniosome gel are prepared by coacervation phase separation method, using different concentration of non ionic surfactant(span and brij)and evaluated various parameter like surface characterization, entrapment efficiency, drug content, viscosity, in vitro % drug release, invitro antifungal activity, invivo study of different optimized formulation.In this investigation, we used a variety of surfactants, including span 40, 60, 80, and brij 35 and Brij 72, in various gel formulations and analysed. As a result, the optimized formulation of proniosome oxymetazoloine hydrochloride (SK723) transparent gel is a vesicle size312.5±0.3 and % entrapment efficiency 81.22±1.62 and % amount of drug release 85.37±0.45, highest drug content, compared to other formulation, indicate a stable gel